Literature DB >> 15573103

Making protein interactions druggable: targeting PDZ domains.

Kumlesh K Dev1.   

Abstract

Modulating protein-protein interactions involved in disease pathways is an attractive strategy for developing drugs, but remains a challenge to achieve. One approach is to target certain domains within proteins that mediate these interactions. One example of such a domain is the PDZ domain, which is involved in interactions between many different proteins in a variety of cellular contexts. Because PDZ domains have well-defined binding sites, they are promising targets for drug discovery. However, there is still much to learn about the function of these domains before drugs targeting PDZ interactions can become a reality.

Mesh:

Substances:

Year:  2004        PMID: 15573103     DOI: 10.1038/nrd1578

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  77 in total

1.  Characterization of PDZ domain-peptide interactions using an integrated protocol of QM/MM, PB/SA, and CFEA analyses.

Authors:  Feifei Tian; Yonggang Lv; Peng Zhou; Li Yang
Journal:  J Comput Aided Mol Des       Date:  2011-10-01       Impact factor: 3.686

2.  The PDZ1 and PDZ3 domains of MAGI-1 regulate the eight-exon isoform of the coxsackievirus and adenovirus receptor.

Authors:  Abimbola Olayinka Kolawole; Priyanka Sharma; Ran Yan; Kyle Joseph Edward Lewis; Zhigang Xu; Heather Ann Hostetler; Katherine Julie Diane Ashbourne Excoffon
Journal:  J Virol       Date:  2012-06-20       Impact factor: 5.103

3.  GLAST stability and activity are enhanced by interaction with the PDZ scaffold NHERF-2.

Authors:  Stefanie L Ritter; Matthew J Asay; Maryse Paquet; Kevin J Paavola; Rachel E Reiff; C Chris Yun; Randy A Hall
Journal:  Neurosci Lett       Date:  2010-04-27       Impact factor: 3.046

4.  Structure of PICK1 and other PDZ domains obtained with the help of self-binding C-terminal extensions.

Authors:  Jonathan M Elkins; Evangelos Papagrigoriou; Georgina Berridge; Xiaowen Yang; Claire Phillips; Carina Gileadi; Pavel Savitsky; Declan A Doyle
Journal:  Protein Sci       Date:  2007-04       Impact factor: 6.725

5.  PDZ domains at excitatory synapses: potential molecular targets for persistent pain treatment.

Authors:  Yuan-Xiang Tao; Roger A Johns
Journal:  Curr Neuropharmacol       Date:  2006-07       Impact factor: 7.363

Review 6.  Proteomic approaches and identification of novel therapeutic targets for alcoholism.

Authors:  Giorgio Gorini; R Adron Harris; R Dayne Mayfield
Journal:  Neuropsychopharmacology       Date:  2013-07-31       Impact factor: 7.853

Review 7.  CFTR chloride channel in the apical compartments: spatiotemporal coupling to its interacting partners.

Authors:  Chunying Li; Anjaparavanda P Naren
Journal:  Integr Biol (Camb)       Date:  2010-03-05       Impact factor: 2.192

Review 8.  Viral infection and human disease--insights from minimotifs.

Authors:  Krishna Kadaveru; Jay Vyas; Martin R Schiller
Journal:  Front Biosci       Date:  2008-05-01

Review 9.  Therapeutic use of PDZ protein-protein interaction antagonism.

Authors:  Nick X Wang; Ho-Jin Lee; Jie J Zheng
Journal:  Drug News Perspect       Date:  2008-04

10.  Identification of a small-molecule inhibitor of the PICK1 PDZ domain that inhibits hippocampal LTP and LTD.

Authors:  Thor S Thorsen; Kenneth L Madsen; Nelson Rebola; Mette Rathje; Victor Anggono; Anders Bach; Irina S Moreira; Nicolai Stuhr-Hansen; Tino Dyhring; Dan Peters; Thijs Beuming; Richard Huganir; Harel Weinstein; Christophe Mulle; Kristian Strømgaard; Lars Christian B Rønn; Ulrik Gether
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-14       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.